News Release：2025 | Eisai Co., Ltd.

October 20, 2025

LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen
At five years, LENVIMA plus KEYTRUDA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy alone in the pivotal Phase 3 Study 309/KEYNOTE-775 trial

Five-year OS results in the pMMR subgroup were consistent with the all-comers study population, which demonstrated an OS rate of 19.9% for LENVIMA plus KEYTRUDA versus 7.7% for chemotherapy

October 14, 2025

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”

October 7, 2025

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease
New LEQEMBI CompanionTM program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training,and an injection tracking tool and more

LEQEMBI IQLIK, approved by the U.S. FDA in August 2025, is the first and only anti-amyloid treatment to offer an at-home injection after initial treatment of 18 months

October 2, 2025

Eisai Highlights Breadth of Oncology Research at ESMO 2025

September 29, 2025

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China

September 24, 2025

LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia

September 24, 2025

Notice of the Settlement of Patent Infringement Litigation Related to Lenvatinib in the U.S.

September 17, 2025

Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation

September 12, 2025

“New Answers to Dementia”
Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month

September 8, 2025

Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
E2086 Showed Potential to Improve Wakefulness in People Living with Narcolepsy Type 1

September 4, 2025

Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025

September 3, 2025

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive, relentless disease

August 30, 2025

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initial treatment of 18 months
LEQEMBI IQLIK will be launched on October 6, 2025, in the U.S.

August 29, 2025

Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to
Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma

August 25, 2025

Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)

August 18, 2025

Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO® (Lemborexant) in China

July 31, 2025

Revenue of LEQEMBI® (Preliminary Basis)

July 31, 2025

Early Alzheimer’s Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
Data Showed LEQEMBI Slowed Clinical Decline by 1.75 Points on CDR-SB at Four Years Compared to the Natural History of Alzheimer’s Disease

56% of Patients with Low Tau Continued to Demonstrate Improved Cognitive and Daily Living Function at Four Years

July 31, 2025

New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer’s Disease
Lecanemab subcutaneous autoinjector has the potential to become a new expanded treatment option for patients with early Alzheimer’s disease, their care partners and healthcare professionals, with results showing a comparable efficacy and safety profile to the intravenous formulation

July 31, 2025

Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025

July 29, 2025

LENVIMA® (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma

July 25, 2025

Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment

July 23, 2025

Launch of Beova® Tablets in Thailand for Overactive Bladder

July 22, 2025

Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer’s Association International Conference 2025
Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline include results from lecanemab long-term data, an immunoassay for measuring amyloid-β protofibrils in cerebrospinal fluid, and a subcutaneous form of lecanemab for continued treatment of AD
AD is a progressive, relentless disease caused by a continuous underlying neurotoxic process that begins before and continues after plaque deposition

July 16, 2025

Eisai Awarded “The 9th Bioindustry Award”
for Drug Discovery Research for Anti- Amyloid β Monoclonal Antibody Lecanemab

July 14, 2025

“URECE®” (Dotinurad) Launched in China as a treatment for Gout

July 9, 2025

Update on the Cost-Effectiveness Evaluation of LEQEMBI® by the Central Social Insurance Medical Council of Japan’s Ministry of Health, Labour and Welfare

July 8, 2025

Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment

June 2, 2025

Eisai to Launch “Pariet® S,” the First Proton Pump Inhibitor RX-to-OTC in Japan
- Same Dosage of the Active Ingredient Rabeprazole Sodium as the Prescription Product -

May 29, 2025

Eisai Obtains Favorable Decision in Patent Infringement Litigation Related to Lenvatinib in the U.S.

May 27, 2025

New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO® (Lemborexant) in China

May 21, 2025

Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025

May 16, 2025

Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro®

May 15, 2025

Notification Regarding Partial Amendment to the Articles of Incorporation

May 8, 2025

Notice Concerning Results of Tender Offer for Share Certificates, etc., of EcoNaviSta Inc. (Securities Code: 5585)

May 1, 2025

REVENUE OF LEQEMBI® (PRELIMINARY BASIS)

April 29, 2025

Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star

April 16, 2025

Leqembi® (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*) non-carriers or heterozygotes with confirmed amyloid pathology
Lecanemab is the first therapy that targets an underlying cause of the disease to be authorized in the EU for eligible people with early AD

April 14, 2025

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease by the European Commission

April 1, 2025

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease by the European Commission

March 28, 2025

“New Answers to Dementia”
Eisai Launches Corporate Awareness Campaign

March 28, 2025

EISAI TO DIVEST RIGHTS FOR PARIET® IN CHINA TO PEAK PHARMA

March 27, 2025

Eisai to Divest Rights for Warfarin in Japan to Sawai

March 27, 2025

Eisai to Present the Latest Research Results, Including Long-Term and
Real-Word Data on Lecanemab and Biomarkers for Alzheimer’s Disease at the AD/PD™ 2025 Annual Meeting

March 25, 2025

World’s First Early Alzheimer’s Disease Treatment Developed in Japan LEQEMBI® Receives Prime Minister’s Award at the 12th Technology Management and Innovation Awards

March 24, 2025

EISAI SELECTED AS A NADESHIKO BRAND 2025 AS A LISTED COMPANY EXCELLING IN PROMOTION OF WOMEN IN THE WORKPLACE

March 21, 2025

Proton Pump Inhibitor “Pariet® S” Approved in Japan as RX-to-OTC Switch
Same Dosage of the Active Ingredient Rabeprazole Sodium as the Prescription Product

March 14, 2025

Notice Concerning Commencement of Tender Offer by Eisai Co., Ltd. for Share Certificates, etc., of EcoNaviSta Inc. (Securities Code: 5585)

March 10, 2025

EISAI RECOGNIZED AS “2025 KENKO INVESTMENT FOR HEALTH” FOR THE FIRST TIME AND CERTIFIED AS “OUTSTANDING ORGANIZATION OF KENKO INVESTMENT FOR HEALTH PROGRAM (WHITE 500)” FOR THE SIXTH TIME

March 7, 2025

Eisai Announces Appointments of Corporate Officers

March 7, 2025

Notice of Nominees for Directors

March 7, 2025

Notification Regarding Changes in Representative Corporate Officers

March 4, 2025

UPDATE ON THE CO-PROMOTION OF THE ORAL ANTIFUNGAL AGENT NAILIN® CAPSULES 100MG IN JAPAN

March 3, 2025

Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia

March 3, 2025

“Fatigue Recovery While You Sleep!” Eisai to Launch Designated Quasi-Drug Drink “Chocola BB® Nightwell”
Easy-To-Drink Grapefruit Flavor Containing Herbal Medicines and Glycine

February 28, 2025

The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer’s Disease

February 28, 2025

Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone

February 20, 2025

EISAI SELECTED FOR “HUMAN CAPITAL LEADERS 2024” AND “HUMAN CAPITAL MANAGEMENT GOLD QUALITY” FOR SECOND CONSECUTIVE YEAR,
AS A COMPANY COMMITTED TO EXCELLENT MANAGEMENT AND DISCLOSURE OF HUMAN CAPITAL INITIATIVES

February 14, 2025

DEVELOPMENT OF PREDICTION MODEL FOR BRAIN AMYLOID-BETA ACCUMULATION FOR EARLY SCREENING OF ALZHEIMER’S DISEASE
MACHINE LEARNING MODEL USING DATA THAT CAN BE COLLECTED IN DAILY MEDICAL EXAMINATIONS BY PRIMARY CARE PHYSICIANS

February 6, 2025

Eisai Rated “A”, the Highest Rating by CDP in the Categories of Climate Change and Water Security

February 3, 2025

Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies

January 31, 2025

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

January 27, 2025

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of
Early Alzheimer’s Disease
Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment

Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with LEQEMBI can slow disease progression and prolong the benefits of therapy

January 24, 2025

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-015 Trial Evaluating LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma

January 23, 2025

Eisai Releases Corporate Film “1 Percent, 1 Mission. Change the World.”

January 22, 2025

EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE NINTH TIME
HIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY

January 14, 2025

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience
of a subcutaneous injection with at-home administration option

January 7, 2025

Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer’s Disease